Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes

KP Minneman, TL Theroux, S Hollinger, C Han and TA Esbenshade

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322.

The potencies and intrinsic activities of agonists in activating cloned alpha 1-adrenergic receptor (AR) subtypes were compared. The hamster alpha 1B-, bovine alpha 1C-, or rat alpha 1A/D-ARs were expressed at high levels in human embryonic kidney 293 cells. Catecholamines and phenylethylamines, but not lower efficacy agonists, were more potent in inhibiting radioligand binding to the expressed alpha 1A/D subtype than to the alpha 1B or alpha 1C subtypes; this selectivity remained in the presence of different buffers, nucleotides, and cations. Activation of all three subtypes caused substantial increases in [3H]inositol phosphate formation in cells grown in 96-well plates. Pretreatment with phenoxybenzamine decreased maximal responses to norepinephrine (NE) with only small decreases in apparent potency, suggesting similar small receptor reserves for all three subtypes. The catecholamines NE, epinephrine, and 6-fluoro-NE were full agonists with similar potencies at the three subtypes; alpha-methyl-NE was also a full agonist but was about 20-fold less potent at alpha 1B-ARs than at alpha 1C- or alpha 1A/D-ARs. Phenylephrine had similar potencies at all three subtypes but gave a submaximal response at alpha 1B-ARs. Methoxamine was a full agonist at alpha 1C- and alpha 1A/D-ARs, with about 20-fold greater potency at the alpha 1C subtype, but showed lower intrinsic activity at alpha 1B-ARs. A number of imidazolines, amidephrine, and SKF 89748 had substantial intrinsic activity at alpha 1C-ARs but little or no intrinsic activity at the other two subtypes. We conclude that the potencies of many agonists in competing for radioligand binding sites are related to their potencies in activating functional responses but that this relationship is not the same for all subtypes. NE and epinephrine activate all three cloned alpha 1-AR subtypes with similar potencies and intrinsic activities, but many widely used agonists show significant selectivity for different alpha 1-AR subtypes.

Volume 46, Issue 5, pp. 929-936, 11/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. S. Laird, A. M. Finch, P. M. E. Waite, and P. Carrive Peripheral changes above and below injury level lead to prolonged vascular responses following high spinal cord injury Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H785 - H792. [Abstract] [Full Text] [PDF]

				D. Marti, R. Miquel, K. Ziani, R. Gisbert, M. D. Ivorra, E. Anselmi, L. Moreno, V. Villagrasa, D. Barettino, and P. D'Ocon Correlation between mRNA levels and functional role of {alpha}1-adrenoceptor subtypes in arteries: evidence of {alpha}1L as a functional isoform of the {alpha}1A-adrenoceptor Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1923 - H1932. [Abstract] [Full Text] [PDF]

				S. Y. Kamikihara, A. Mueller, V. Lima, A. R. T. Silva, I. B. d. Costa, J. Buratini Jr., and A. S. Pupo Differential Distribution of Functional {alpha}1-Adrenergic Receptor Subtypes along the Rat Tail Artery J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 753 - 761. [Abstract] [Full Text] [PDF]

				C. Hague, P. J. Gonzalez-Cabrera, W. B. Jeffries, and P. W. Abel Relationship between alpha 1-Adrenergic Receptor-Induced Contraction and Extracellular Signal-Regulated Kinase Activation in the Bovine Inferior Alveolar Artery J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 403 - 411. [Abstract] [Full Text] [PDF]

				C. McWhinney, D. Wenham, S. Kanwal, V. Kalman, C. Hansen, and J. D. Robishaw Constitutively Active Mutants of the alpha 1a- and the alpha 1b-Adrenergic Receptor Subtypes Reveal Coupling to Different Signaling Pathways and Physiological Responses in Rat Cardiac Myocytes J. Biol. Chem., January 21, 2000; 275(3): 2087 - 2097. [Abstract] [Full Text] [PDF]

				J. E. Porter, S. E. Edelmann, D. J. Waugh, M. T. Piascik, and D. M. Perez The Agonism and Synergistic Potentiation of Weak Partial Agonists by Triethylamine in alpha 1-Adrenergic Receptor Activation: Evidence for a Salt Bridge as the Initiating Process Mol. Pharmacol., April 1, 1998; 53(4): 766 - 771. [Abstract] [Full Text]

				D. J. J. Waugh, R. J. Gaivin, M. J. Zuscik, P. Gonzalez-Cabrera, S. A. Ross, J. Yun, and D. M. Perez Phe-308 and Phe-312 in Transmembrane Domain 7 Are Major Sites of alpha 1-Adrenergic Receptor Antagonist Binding. IMIDAZOLINE AGONISTS BIND LIKE ANTAGONISTS J. Biol. Chem., June 29, 2001; 276(27): 25366 - 25371. [Abstract] [Full Text] [PDF]

				H. Wang, B. Yang, Y. Zhang, H. Han, J. Wang, H. Shi, and Z. Wang Different Subtypes of alpha 1-Adrenoceptor Modulate Different K+ Currents via Different Signaling Pathways in Canine Ventricular Myocytes J. Biol. Chem., October 26, 2001; 276(44): 40811 - 40816. [Abstract] [Full Text] [PDF]